Evidence map›Paper›PMID 39578340›Full record

ReviewMolecular neurobiology2025

Resveratrol: A Natural Compound Targeting the PI3K/Akt/mTOR Pathway in Neurological Diseases.

Biswajit Kumar Utpal, Fatima Zohra Mokhfi, Mehrukh Zehravi, Sherouk Hussein Sweilam, Jeetendra Kumar Gupta, Shaik Kareemulla, Ronald Darwin C, A Anka Rao, Voleti Vijaya Kumar, Pavankumar Krosuri and 6 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Systematic evaluation and comparison of theCurrent research in food science · 2026
    Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Biswajit Kumar Utpal *Department of Pharmacy, Faculty of Health and Life Sciences, Daffodil International University, Dhaka, 1207, Bangladesh.
Fatima Zohra MokhfiLaboratory of AgroBiotechnology and Nutrition in Semi Arid Zones, Faculty of Nature and Life Sciences, University of Ibn Khaldoun, Tiaret, Algeria.
Mehrukh Zehravi *Department of Clinical Pharmacy, College of Dentistry & Pharmacy, Buraydah Private Colleges, Buraydah, 51418, Saudi Arabia. mahrukh.zehravi@hotmail.com.
Sherouk Hussein SweilamDepartment of Pharmacognosy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, 11942, Saudi Arabia.
Jeetendra Kumar GuptaDepartment of Pharmacology, Institute of Pharmaceutical Research, GLA University Mathura, Chaumuha, Mathura, Uttar Pradesh, 281406, India.
Shaik KareemullaDepartment of Pharmacy Practice, Malla Reddy College of Pharmacy (MRCP), Kompally, Secunderabad, Telangana, 500100, India.
Ronald Darwin CDepartment of Pharmacology, School of Pharmaceutical Sciences, Technology and Advanced Studies (VISTAS), Vels Institute of Science, Pallavaram, Chennai, 600117, India.
A Anka RaoKL College of Pharmacy, Koneru Lakshmaiah Education Foundation, Vaddeswaram, Guntur, Andhra Pradesh, 522502, India.
Voleti Vijaya KumarDepartment of Pharmaceutics, School of Pharmacy, Satyabhama Institute of Science and Technology, Chennai, Tamil Nadu, India.
Pavankumar KrosuriDepartment of Pharmaceutics, Santhiram College of Pharmacy, NH40, Nandyal, Andhra Pradesh, 518112, India.
Dharani PrasadDepertment of Pharmacology Mohan Babu University MB School of Pharmaceutical Sciences, Erstwhile Sree Vidyaniketan College of Pharmacy, Tirupati, Andhra Pradesh, 517102, India.
Sharukh L KhanDepartment of Pharmaceutical Chemistry, N.B.S. Institute of Pharmacy, Ausa, 413520, Maharashtra, India.
Sajib Chandra RoyDepartment of Pharmacy, Faculty of Pharmacy, University of Dhaka, Dhaka, 1000, Bangladesh.
Safia Obaidur RabDepartment of Clinical Laboratory Sciences, College of Applied Medical Science, King Khalid University, Abha, Saudi Arabia.
Mohammed Ali AlshehriDepartment of Biology, Faculty of Science, University of Tabuk, Tabuk, 71491, Saudi Arabia.
Talha Bin EmranDepartment of Pharmacy, Faculty of Health and Life Sciences, Daffodil International University, Dhaka, 1207, Bangladesh. talhabmb@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurological diseases (NDs), including neurodegenerative disorders and acute injuries, are a significant global health concern. The PI3K/Akt/mTOR pathway, a crucial signaling cascade, is responsible for the survival of cells, proliferation, and metabolism. Dysregulation of this pathway has been linked to neurological conditions, indicating its potential as a vital target for therapeutic approaches. Resveratrol (RSV), a natural compound found in berries, peanuts, and red grapes, has antioxidant, anti-cancer, and anti-inflammatory effects. Its ability to modulate the PI3K/Akt/mTOR pathway has been interesting in NDs. Studies have shown that RSV can activate the PI3K/Akt pathway, promoting cell survival and inhibiting apoptosis of neuronal cells. Its impact on mTOR, a downstream effector of Akt, further contributes to its neuroprotective effects. RSV's ability to restore autophagic flux presents a promising avenue for therapeutic intervention. Its anti-inflammatory properties suppress inflammatory responses by inhibiting key signaling molecules within the pathway. Additionally, RSV's role in enhancing mitochondrial function contributes to its neuroprotective profile. This study highlights RSV's potential as a multifaceted therapeutic agent in NDs, specifically by PI3K/Akt/mTOR pathway modulation. Additional investigation is required to optimize its therapeutic capacity in diverse neurological conditions.

Indexed as

Biological ProductsNervous System DiseasesPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktResveratrolSignal TransductionTOR Serine-Threonine KinasesAnimalsHumansNeuroprotective AgentsBiological ProductsNeuroprotective AgentsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktResveratrolTOR Serine-Threonine KinasesClinical studiesNeurological diseasesPI3K/Akt/mTOR pathwayResveratrol

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.